Jiangsu Changyou Environmental Protection Technology
301557
Hefei conver Holding
603409
LIERDA
832149
4
SHENGNAN TECHNOLOGY
837006
5
CHK
831167
US Stock MarketDetailed Quotes
TRVI Trevi Therapeutics
- 4.440
- +0.180+4.23%
Close Mar 4 16:00 ET
- 4.500
- +0.060+1.35%
Post 17:29 ET
396.78MMarket Cap-10.09P/E (TTM)
4.520High4.220Low1.12MVolume4.340Open4.260Pre Close4.90MTurnover1.68%Turnover RatioLossP/E (Static)89.37MShares5.05052wk High6.73P/B294.74MFloat Cap2.30052wk Low--Dividend TTM66.38MShs Float10.620Historical High--Div YieldTTM7.04%Amplitude0.460Historical Low4.394Avg Price1Lot Size
Trending Stocks
Discussing
As China's 'two sessions' approach: How will Chinese stocks perform?
🎙️Discussion 1. With China's 'two sessions' approaching, do you focus more on policy dynamics or capital flows? 2. Which industry sectors d
Moomoo News Global
Feb 24 22:30
Chinese Stocks' Wild Rally Hits Pause? Wall Street Still Bets Big on Favorites
Trevi Therapeutics Stock Forum
Can Trevi's Haduvio Break Through Where Others Failed? Key IPF Cough Trial Fully Enrolled
Trevi Therapeutics Completes Enrollment for Phase 2B Coral Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients With Chronic Cough! Results expected in first half of 2025
📊⚡️📊
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
Thursday, 12th December at 7:30 am
Independent Data Monitoring Statistician reaffirmed current sample size to remain at N=160
The trial has reached 75% of the targeted enrollment, and topline results continue to be expected in the first half of 20...
Trevi Therapeutics Announces Positive Outcome From SAMPLE Size Re-Estimation Resulting in No Change to the Current SAMPLE Size for the Phase 2B Coral Trial in Idiopathic Pulmonary Fibrosis Patients With Chronic Cough
No comment yet